Hi -,
On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee votes on whether to add seven peptides to the 503A Bulks List. BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. Five more come up for review before February 2027.
This is the most movement the peptide space has seen in a decade, and it is the start of a conversation we are going to have with you over the coming weeks.
Why this vote matters
The 503A Bulks List is the FDA's roster of substances that licensed compounding pharmacies are allowed to prepare with a prescription. When a peptide lands on that list, a clinician can write a prescription, and a licensed pharmacy makes it under the same sterility, purity, and potency standards as any other medication.
That changes the picture. The vial arrives ready, dosed, and accounted for. The molecule on the label is the molecule inside the vial. No reconstitution math with bacteriostatic water. No wondering about endotoxins or heavy metals. No guessing whether the (possibly questionable) “pharmacy” across the country actually made what they said they made.
The seven peptides on the ballot
Each of these has a mechanism worth understanding, and we are going to unpack them one at a time in the coming weeks. The short version:
-
BPC-157. The Body Protection Compound. Triggers angiogenesis (new blood vessel formation) at injury sites and supports tissue repair across tendon, ligament, gut barrier, and peripheral nerve. The peptide is named for what it does.
-
TB-500. Coordinates the cellular migration that moves repair cells to damaged muscle, tendon, and ligament. Pairs with BPC-157 to cover both the blood supply and the cellular workforce behind tissue repair.
- KPV. A three-amino-acid anti-inflammatory peptide active across the gut and skin barrier. Small molecule, broad mucosal reach.
-
MOTS-c. A peptide your own mitochondria produce. Activates AMPK and supports mitochondrial function, insulin sensitivity, and the metabolic signal of exercise. The cell's own training-amplification molecule.
- DSIP. Delta-sleep-inducing peptide. Modulates sleep architecture (deep sleep ratio, REM preservation) and dampens cortisol, rather than forcing sedation.
-
Semax. Upregulates BDNF and NGF, two of the brain's own growth factors. Supports sustained attention and neuroprotection, with over twenty years of clinical use in Russia for cognitive and post-stroke applications.
- Epitalon. Emerging research only. A proposed telomerase signal molecule with a long Russian gerontology literature and limited published human data.
Faster recovery from training and injury. Sleep that actually rebuilds you. Sustained attention without stimulant burnout. Stronger mitochondrial and metabolic function. Tissue repair that keeps pace with what you ask of your body. These compounds work on pathways your body already runs; what they do is sharpen the signal.
The longer-term win is the data
Here is the part that excites me the most. Every prescription written for a Category 1 peptide creates a record. The dose, the indication, the labs before and after, the side effects, the interactions a clinician catches when a client is also on testosterone, a GLP-1, or an SSRI.
Multiply that across many thousands of clients, and the field finally has what it has never had: a clear picture of what dose works for what condition, who should not be using these compounds, and how they behave alongside everything else someone might be on. That is how dosing standards get written. That is how clinical guidelines come together. And that is the pathway by which the next round of peptides gets added to the list, because the FDA reviews the evidence the field produces.
The benefit reaches further than the prescribed route. The dosing data, the safety signals, the indication and contraindication work all become public knowledge that the wider community can read and apply, whether or not they ever fill a prescription.
What's next from us
Over the coming weeks, we are going to take each of these seven peptides apart in their own email. What they do at the mechanism level. Who they are for. What the evidence actually says. What a protocol looks like in practice. We will keep you posted on the July vote as it gets closer.
This is a moment worth paying attention to.
Dr. Gabriel Alizaidy
Scientific Director, Maximus
Athlete advisory. BPC-157 and TB-500 are listed as prohibited substances under WADA and USADA. Competitive athletes subject to testing should not use peptides containing them. A licensed provider will discuss this with you during evaluation.
